` NVAX (Novavax Inc) vs S&P 500 Comparison - Alpha Spread

NVAX
vs
S&P 500

Over the past 12 months, NVAX has underperformed S&P 500, delivering a return of -57% compared to the S&P 500's +14% growth.

Stocks Performance
NVAX vs S&P 500

Loading
NVAX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
NVAX vs S&P 500

Loading
NVAX
S&P 500
Difference
www.alphaspread.com

Performance By Year
NVAX vs S&P 500

Loading
NVAX
S&P 500
Add Stock

Competitors Performance
Novavax Inc vs Peers

S&P 500
NVAX
ABBV
CYTH
AMGN
GILD
Add Stock

Novavax Inc
Glance View

Nestled at the intersection of innovation and dedication, Novavax Inc. emerged as a pivotal player in the biopharmaceutical landscape. Founded in 1987, the company was initially envisioned to be a biotechnology firm focused on life-saving vaccines, a mission that would increasingly align with global needs. Through diligent research and development, Novavax adopted a recombinant nanoparticle technology platform, enabling the company to develop distinctive vaccines. Using proprietary adjuvants to bolster immune responses, their work is characterized by precision and high efficacy. Novavax’s journey gained substantial momentum during the COVID-19 pandemic, as the urgent demand for vaccines spotlighted their potential. The development of their COVID-19 vaccine candidate, leveraging this cutting-edge technology, became a critical milestone, underscoring their adaptability and competence in addressing modern health challenges. From a business perspective, Novavax crafts its success by guiding innovative vaccine candidates through rigorous stages of clinical trials and regulatory approvals, ultimately leading to revenue generation via licensing agreements and government contracts. They meticulously balance risk and opportunity by targeting a spectrum of infectious diseases, aiming to broaden their product pipeline and thus capture larger market shares. Revenue flows primarily from the sale of these vaccines, which are distributed worldwide, and the company continues to explore partnerships and collaborations to enhance its market reach. Novavax showcases resilience and forward-thinking strategies, underpinned by a commitment to expanding access to essential vaccines globally, thereby meeting both public health needs and corporate growth objectives.

NVAX Intrinsic Value
6.71 USD
Overvaluation 4%
Intrinsic Value
Price
Back to Top